Tarsus Pharmaceuticals, Inc. (TARS)
NASDAQ: TARS · Real-Time Price · USD
62.48
-2.70 (-4.14%)
At close: May 15, 2026, 4:00 PM EDT
61.00
-1.48 (-2.37%)
After-hours: May 15, 2026, 5:00 PM EDT
Tarsus Pharmaceuticals Stock Forecast
Stock Price Forecast
The 5 analysts that cover Tarsus Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $96.6, which forecasts a 54.61% increase in the stock price over the next year. The lowest target is $88 and the highest is $105.
Price Target: $96.6 (+54.61%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Tarsus Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 2 |
| Buy | 4 | 4 | 4 | 4 | 4 | 3 |
| Hold | 1 | 1 | 1 | 1 | 1 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 9 | 9 | 9 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $88 | Strong Buy | Reiterates | $88 | +40.85% | May 4, 2026 |
| Oppenheimer | Oppenheimer | Buy Maintains $95 → $105 | Buy | Maintains | $95 → $105 | +68.05% | Feb 25, 2026 |
| Guggenheim | Guggenheim | Strong Buy Maintains $87 → $90 | Strong Buy | Maintains | $87 → $90 | +44.05% | Feb 25, 2026 |
| Barclays | Barclays | Buy Initiates $100 | Buy | Initiates | $100 | +60.05% | Dec 9, 2025 |
| Mizuho | Mizuho | Buy Initiates $100 | Buy | Initiates | $100 | +60.05% | Nov 20, 2025 |
Financial Forecast
Revenue This Year
706.29M
from 451.36M
Increased by 56.48%
Revenue Next Year
920.37M
from 706.29M
Increased by 30.31%
EPS This Year
-0.59
from -1.59
EPS Next Year
3.16
from -0.59
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 742.5M | 1.0B | ||||||
| Avg | 706.3M | 920.4M | ||||||
| Low | 666.9M | 833.0M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 64.5% | 47.0% | ||||||
| Avg | 56.5% | 30.3% | ||||||
| Low | 47.8% | 17.9% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 0.35 | 4.56 | ||||||
| Avg | -0.59 | 3.16 | ||||||
| Low | -0.99 | 2.02 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.